Small Cap Feast
Small Cap Feast – 20 May 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
WorldPay has left the Main Market (standard) today pursuant to a merger with Fidelity National Information Services
WorldPay has left the Main Market (standard) today pursuant to a merger with Fidelity National Information Services
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
Jewel UK Midco Limited, the parent company of The Watches of Switzerland Group Limited, is looking to join the premium segment of the main market. Offer TBC, expect TBC
Main Market (Standard)
IMC Exploration Group (NEX: IMCP), focused on acquiring and exploring prospecting licence areas which have high potential for natural resource, is looking to admit its shares to the standard list and will withdraw for the NEX Exchange. Expected 11 June 2019
Pure Gold— TSX listed seeking a London listing. Focused on Madsen Red Lake Gold Deposit. Feasibility Study outlines a robust 12-year, high grade, 800 tonne per day underground mining operation with low initial capital cost of C$95mm and strong financial performance with an after-tax NPV of C$247mm . Introduction only at this point Mkt cap CA£138m.
Main Market (Specialist Funds)
Riverstone Credit Opportunities Income – raising US$200m—will seek to generate consistent shareholder returns predominantly in the form of income distributions principally by making senior secured loans to energy-related businesses. Due 24 May
Essensys plc—a provider of mission-critical SaaS platforms and on-demand cloud services to the high growth flexible workspace industry, plans to join AIM. Offer TBC, expected 29 May 2019.
Induction Healthcare Group plc—a healthcare technology company focused on streamlining the delivery of care by Healthcare Professionals looking to join AIM. Expected raise of £14.58m at 115p, market cap of £34.07m. Expected 22 May 2019.
SDX Energy plc—a North Africa focused oil and gas company, announces its intention to complete a Canadian plan of arrangement under section 192 of the Canada Business Corporations Act and will have shares de-listed from the TSX-V and admitted to trading on AIM. Expected 28 May 2019, anticipated market cap of £76m
Renold plc—a leading international supplier of industrial chains and related power transmission products, announced that it will cancel the listing of the Company from the premium segment and apply for admission on AIM. Expected 06 June 2019.
Alumasc Group plc, the premium building products, systems and solutions group, has announced its intention to move from the Premium Segment of the main market to AIM. Expected market cap of £33.4m. Expected 25 June 2019
SSuINOx—has developed a hydrocarbon fuels conditioning and emulsifying process that enables more efficient fuel combustion, leading potentially to reduced fuel usage and significantly lowered emissions. Offer TBA.
Scancell Holdings (SCLP.L) 4.25p £16.48m
Scancell Holdings PLC, a developer of novel immunotherapies for the treatment of cancer, and Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research, are pleased to provide an update on their clinical development partnership for the development of Scancell’s ImmunoBody® vaccine, SCIB2, as a potential treatment for patients with solid tumours, including non-small cell lung cancer (NSCLC). “
Pre-clinical studies have demonstrated that administration of SCIB2 as a liposomal nanoparticle results in potent immune responses and prolonged survival.
Cancer Research UK are now planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.
Volga Gas (VGAS.L) 82.84p £66.74m
AGM Statement from the oil and gas exploration and production group operating in the Volga Region of Russia .
- Between 1 January and 30 April 2019, Group production averaged 5,859 barrels of oil equivalent per day (“boepd”).
- Between 1 January and 30 April 2019, realised prices for oil and condensate net of sales expenses averaged $39.36 per barrel.
- The Group’s cash position as at 30 April 2019 was US$14.8m (US$15.2m at 31 December 2018), after payment of approximately US$2.2m on capital expenditure, repaying the full outstanding balance of US$1.7m of bank debt, and purchasing 450,000 of the Company’s shares in the market.
- The Group has been debt-free since February 2019.
Reabold Resources (RBD.L) 0.7p £26.7m
Integrity Management Solutions (“IMS”), contract operator of Reabold’s interests in California, has informed the Company that the perforating and swabbing operation at the Burnett 2B and Burnett 2A wells, as announced on 29 April 2019, has been completed. Commercial flow rates have been confirmed at both wells, which are the third and fourth wells in the Reabold California portfolio to achieve this.
Multiple zones were perforated in both wells and the swabbing runs resulted in oil flow from all zones prognosed to be hydrocarbon bearing.
Pumping units are being mobilised this week, with the final permanent production facilities expected to be in place within the next two weeks, at which point both wells will be put onto permanent production. Reabold will inform the market as to the flow rates achieved once the wells are on permanent production.
AFC Energy (AFC.L) 4.741p £20.2m
The alkaline fuel cell power company, announces the successful results of an 18 month Ammonia to Power (“A2P”) trial and confirms plans to conclude work on the business case and engineering of an integrated, scalable ammonia fuelled clean power generator.
The system, which expects to utilise existing ammonia cracking technology alongside AFC Energy’s proprietary fuel cell system, would enable the use of AFC Energy’s fuel cells in off-grid locations where electricity would be generated through the consumption of ammonia; a low-cost commodity chemical that is readily available in industrialised and developing countries.
- Negligible difference in fuel-cell performance witnessed between direct hydrogen gas sourced from industrial gas companies, and that sourced from cracked ammonia
- Ability to utilise “off the shelf” ammonia crackers readily available in today’s market without the need for further research and development costs that would otherwise likely delay go to market strategies
Allergy Therapeutics (AGY.L) 12.5p £79.5m
The fully integrated commercial biotechnology company specialising in allergy vaccines, today announces positive Phase I safety and tolerability results of subcutaneous Acarovac MPL (Monophosphoryl Lipid A) in patients with house dust mite (HDM)-induced allergic rhinoconjunctivitis.
The primary endpoint was the safety and tolerability of 7 injections of Acarovac MPL administered over 6-12 weeks each 1-2 weeks apart. The formulation was well tolerated. The safety profile was satisfactory and the reported adverse events were consistent with what have been observed with similar formulations of allergy vaccines.
A significant improvement from baseline in patients’ total symptom scores following NPT after 12 weeks, and significant increases in immunoglobulin markers and reduction in IL-4 were observed.
AB Dynamics (ABDP.L) 2410p £471m
Proposed Placing to raise up to £45.1m via an accelerated bookbuild the designer, manufacturer and supplier of advanced testing systems and measurement products for the global automotive market, lus £5m open offer. Issue price 2200p.
The Company intends to use the net proceeds of the proposed Placing in support of the Company’s stated strategy to finance potential acquisition opportunities, adding important production capacity and for ongoing working capital requirements.
Iofina (IOF.L) 18.4p £23.5m
The specialists in the exploration and production of iodine and manufacturers of other halogen-based derivatives at its specialty chemical company, today announces a proposed conditional placing, subscription and open offer to raise gross proceeds of up to £7.5m at 16 pence per share.
The net proceeds of the Fundraising will enable Iofina to accelerate its plant upgrading programme, which in turn will increase iodine production and sales, as well as reduce the Company’s debt.
The Issue Price represents a discount of approximately 15.8 per cent. to the Closing Price of 19 pence per Ordinary Share on 17 May 2019,.
The City Pub Group (CPC.L) 230p £141m
AGM statement from the owner and operator an estate of premium pubs across the southern half of England and Wales.
Year on year performance continues to be strong following our annual results announcement on 9 April 2019 and, for the 19 weeks to 12 May 2019, sales were up 35% on last year.
“We are continuing to seek further pubs in Southern England and Wales to build the estate and achieve our target of 65-70 sites by mid-2021.” (currently 45 trading and 5 under development).
Actual Experience (ACT.L) 185p £83m
HY Mar 19 results from the analytics-as-a-service company.
“● Deepening of our engagement with our Channel Partners and two further ‘land and expand’ customer deployments secured
- Increased automation and scalability of our Analytics-as-a-Service (“AaaS”), to support our Channel Partners
- Revenue increased to £953,025 (31 March 2018: £264,348), reflecting growth in Channel Partner revenue
- Operating loss reduced to £3,458,087 (31 March 2018: loss of £3,825,738), in line with management expectations”.
- Cash and cash equivalents at 31 March 2019 of £8,166,466 (30 September 2018: £10,776,516)”
Post period end
- First successful evaluation of ‘built in’ Channel Partner achieved, a key strategic milestone”.
Rockfire Resources (ROCK.L) 0.75p £3.24m
The gold and base metal-focused resource company, is pleased to announce that recent soil sampling at the Cardigan Dam Prospect, part of the Lighthouse tenement in Queensland, Australia, has returned a promising gold-in-soil anomaly.
- Two broad gold-in-soil anomalous trends detected
- Each trend is approximately 400m long x 100m wide in dimension
- The anomaly remains open along strike length
- Soil results up to 205ppb (0.2ppm) Au
- 14% of all soil samples have results above 20ppb Au
- Historical rock samples identify anomalous gold up to 11.4 g/t Au at surface
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.